Drug Profile
VS 110
Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Vidasym
- Class Vitamin D analogues
- Mechanism of Action Calcitonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Inflammatory bowel diseases in USA (PO) (Vidasym pipeline, September 2023)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO, Capsule)
- 05 Aug 2016 Preclinical development is ongoing in USA